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The Anaphase-promoting complex/cyclosome
(APC/C) cofactor Cdh1 modulates cell proliferation
by targeting multiple cell-cycle regulators for ubiqui-
tin-dependent degradation. Lack of Cdh1 results in
structural and numerical chromosome aberrations,
a hallmark of genomic instability. By using a proteo-
mic approach in Cdh1-null cells and mouse tissues,
we have identified kinesin Eg5 and topoisomerase
2a as Cdh1 targets involved in the maintenance of
genomic stability. These proteins are ubiquitinated
and degraded through specific KEN and D boxes
in a Cdh1-dependent manner. Whereas Cdh1-null
cells display partial resistance to Eg5 inhibitors
such as monastrol, lack of Cdh1 results in a
dramatic sensitivity to Top2a poisons as a con-
sequence of increased levels of trapped Top2a-DNA
complexes. Chemical inhibition of the APC/C in
cancer cells results in increased sensitivity to
Top2a poisons. This work identifies in vivo targets
of the mammalian APC/C-Cdh1 complex and re-
veals synthetic lethal interactions of relevance in
anticancer treatments.
INTRODUCTION
The eukaryotic cell cycle is tightly regulated through the control
of the protein level and activity of critical enzymes. The
Anaphase-promoting Complex/Cyclosome (APC/C) is a multi-
meric complex that ubiquitinates and targets for degradation
multiple cell-cycle regulators (Peters, 2006). The temporal activ-
ities of the APC/C require two subunits, called cofactors, which
bind and activate this complex at different times. Cdc20
activates the APC/C during mitosis targeting securin and mitotic670 Cell Reports 6, 670–683, February 27, 2014 ª2014 The Authorscyclins for degradation, thus triggering mitotic exit. Cdh1, on
the other hand, replaces Cdc20 during mitotic exit and targets
multiple cell-cycle regulators for degradation, thus preventing
unscheduled entry into S phase and replicative stress (Eguren
et al., 2011; Peters, 2006). Whereas Cdc20 is essential for
the metaphase-to-anaphase transition (Manchado et al.,
2010b), Cdh1 is dispensable for cell-cycle progression from
yeast to mammals (Garcı´a-Higuera et al., 2008). Yet, lack of
mammalian Cdh1 results in pleiotropic defects that include early
entry into S phase, defective chromosome segregation, and
accumulation to polyploid cells, as well as chromosomal and
genomic instability (Garcı´a-Higuera et al., 2008; Li et al., 2008;
Sigl et al., 2009).
Whereas Cdc20 is able to target only a reduced number of
proteins for degradation, the activity of Cdh1 is much more
promiscuous. Known Cdh1 substrates include proteins
involved in mitosis and cytokinesis (A- and B-type cyclins,
Aurora A and B, Tpx2, Plk1, etc.), DNA replication (geminin,
thymidine kinase 1, and thymidylate kinase), neuron biology,
metabolism, etc. (Eguren et al., 2011; Manchado et al.,
2010a; Peters, 2006). Despite the relevance of Cdh1 as a
major regulator of the cell cycle and a critical modulator of
cellular transformation, it is not currently clear which Cdh1
substrates mediate genomic instability or how the defects
found in Cdh1-deficient tumor cells can be manipulated for
therapeutic intervention in cancer. We have used Cdh1-null
cells and mice (Garcı´a-Higuera et al., 2008) to perform an
unbiased analysis of proteins upregulated in the absence of
this APC/C cofactor. Among these proteins, we describe here
the relevance of Eg5 and Top2a, two targets of interest in
cancer therapy. These two proteins are significantly up-
regulated in the absence of Cdh1, in vitro and in vivo, and
are ubiquitinated in an APC/C-Cdh1-dependent manner. In
addition, upregulation of these targets in Cdh1-deficient cells
results in differential responses (increased resistance or sus-
ceptibility) to specific therapeutic agents, thus highlighting the
clinical relevance of these findings.
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Figure 1. Quantitative Proteomics in Cdh1-Null Mouse Embryonic Fibroblasts
(A) The levels of proteins were compared in immortal Fzr1(–/–) or wild-type cells with SILAC. The protein ratios between the heavy (Cdh1-null cells) and light (wild-
type cells) labeled samples are plotted against their protein abundance (estimated as average area of the three unique peptides with the largest peak area per
protein; see Figure S1). Significantly upregulated known substrates are indicated in blue.
(B) iTRAQ analysis in serum-starved MEFs. The ratio between protein levels in Fzr1(–/–) and Fzr1(+/+) MEFs is shown in the x axis as a function of their abun-
dances. Known mammalian substrates are indicated in blue, whereas additional proteins upregulated both in asynchronous and serum-starved cultures are
shown in red.
(C) Correlation between the protein accumulation in asynchronous cultures (y axis) and serum-starved cells (x axis). Known mammalian substrates are indicated
in blue, whereas hits upregulated in both studies are shown in red.
(D) Protein levels of known Cdh1 substrates (Aurora A, Tpx2, Securin, Cyclin B1) and additional hits found in our previous proteomics analyses. Fzr1(+/–) are
heterozygousMEFs carrying a normal allele and a germline, null allele. Fzr1(+/L) carry a lox (L) allele that normally expresses Cdh1. This allele results in a null allele
[Fzr1(D)] after expression of the recombinase Cre.
(E) Protein levels of Eg5 and Top2a in Cdh1-null [Fzr1(–/D)] and control heterozygous [Fzr1(+/D)] MEFs as detected by immunofluorescence. Tpx2 was used as a
control. Scale bars, 50 mm.RESULTS
Quantitative Proteomics Screens in Cdh1-Null Cells
We first analyzed the relative amount of proteins in the absence
of Cdh1 by stable isotope labeling with amino acids in cell
culture (SILAC; see the Experimental Procedures; Figure S1).
We differentially labeled Cdh1- (encoded by the Fzr1 locus in
mammals) deficient [Fzr1(–/–); (Garcı´a-Higuera et al., 2008)]
mouse embryonic fibroblasts (MEFs) and their control [Fzr1
(+/+)] cultures with heavy or light isotopes, respectively. Asyn-
chronous cultures (Figure S2) were harvested, and proteins
were quantified by mass spectrometry. Overall, we were able
to obtain quantitative measurements for 2,324 proteins, from
which 308 showed upregulation in the absence of Cdh1 (protein
log2 ratio >1; equivalent to 2-fold; Figure 1A). Among them, we
found known APC/C-Cdh1 substrates such as Anillin, Kif22,
Ube2s, or Ckap2.CBecause lack of Cdh1 may result in shorter G1 and longer S
phase (Figure S2; Garcı´a-Higuera et al., 2008; Sigl et al., 2009),
we complemented these studies with protein profiles obtained
36 hr after removal of serum, a time in which both wild-type
and Cdh1-null cells are quiescent (Figure S2) and known sub-
strates accumulate in the absence of Cdh1 (Garcı´a-Higuera
et al., 2008). The corresponding protein lysates were then
analyzed by using the isobaric tag for relative and absolute quan-
titation (iTRAQ) technique. The relative levels of 4,198 proteins
were quantified, and 21 proteins were upregulated (log2 ratio
>0.58; equivalent to 1.5-fold) in these Cdh1-null serum-starved
cultures including known mammalian substrates of the APC/C
complex, such as Anillin, Tacc3, Ckap2, or Gtse1. Additional
hits that were also upregulated in the previous analysis in asyn-
chronous cultures (Figure 1A) include Eg5, Top2a, Cbr2, or
Kpna2 (Figures 1B and 1C). The differential expression of several
of these proteins was validated by immunodetection in lysatesell Reports 6, 670–683, February 27, 2014 ª2014 The Authors 671
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Figure 2. Quantitative Proteomics Screens in Cdh1-Deficient Brains
(A) The ratio between protein levels in Fzr1(–/D) and Fzr1(+/D) brains is shown in the x axis against the estimated protein abundance (see also Figure S1).
(B) Correlation between the data from asynchronous cultures in MEFs (y axis) and data in brains (x axis).
(C) Correlation between the data from serum-starved MEFs (y axis) and embryonic brains (x axis). In (A)–(C), known substrates are indicated in blue, whereas
additional proteins upregulated both in MEFs (Figure 1) and brains are shown in red.
(D) Protein levels of molecules found in the proteomics screens in Cdh1-null [Fzr1(D/D)], heterozygous [Fzr1(+/D) and Fzr1(–/L)], and normal [Fzr1(+/L)] E15.5
brains. Known Cdh1 substrates (Aurora A, Tpx2) and control panels are taken from Eguren et al. (2013) with permission.
(E) Immunofluorescence of Eg5 and Top2a in Cdh1-null [Fzr1(D/D)] and control [Fzr1(L/L)] brains.
(F) Immunohistochemistry analysis of known Cdh1 targets (Tpx2, Aurora A and Aurora B) in Cdh1-null [Fzr1(D/D)] and control [Fzr1(L/L)] brains. Nuclei were
counterstained with hematoxylin. Scale bars, 25 mm.from Cdh1-null and control fibroblasts (Figure 1D). The upregu-
lation of two of these candidates, Eg5 and Top2a, was also vali-
dated by immunofluorescence in cultured MEFs (Figure 1E).
We next tested the differential expression of proteins in vivo by
using Cdh1-deficient brains, a tissue in which ablation of the
Cdh1-encoding gene, Fzr1, results in developmental defects
(Eguren et al., 2013). Given that Cdh1 is essential for endorepli-
cation in placental trophoblast giant cells, we used Sox2-Cre
mice to specifically ablate Cdh1 in the embryo but not in
placental tissues (Garcı´a-Higuera et al., 2008). Brains from em-
bryonic day (E)15.5 Fzr1(–/D); Sox2-Cre and control embryos
were differentially labeled with iTRAQ reagents and analyzed
by mass spectrometry (Figure S1). This analysis provided quan-
titative data for 3,466 proteins, from which 31 were upregulated
more than 1.5-fold (log2 ratio > 0.58) in Cdh1-null brains,
including the known substrates Tacc3, Aurora B, Nusap1,
Ndc80, and Ckap2 (Figure 2A). Interestingly, three of the most
differentially expressed proteins found in Cdh1-null MEFs, Eg5,
Top2a, and Kpna2 were also upregulated in Cdh1-null brains672 Cell Reports 6, 670–683, February 27, 2014 ª2014 The Authors(Figures 2A–2C). These results were validated by immunoblot
(Figure 2D) or immunofluorescence (Figures 2E and 2F) analysis
using brains from different E14.5–16.5 Cdh1-null and control
embryos.
Nine proteins were found consistently upregulated in the three
different systems (asynchronous MEFs, serum-starved MEFs,
and embryonic brains) or were upregulated in two of them and
not detected in the third one (Table 1). This set of nine proteins
was enriched in known mammalian Cdh1 substrates (3/9 =
33% versus 29 known substrates [Table S1] among the 5,997
proteins [0.5%] analyzed in this study; p < 0.001). Some other
known substrates were only upregulated or detected in one of
the three studies or were not upregulated (Table S1). In addition,
five of the proteins selected in Table 1 contain KEN boxes (56%
versus 11% in the 5,997 proteins identified in these studies; p <
0.0001). Four of them (44%) also contained aDbox as defined by
the R-X-X-L-X-[LIVM] sequence, although this percentage was
not significantly different from that found in the whole set of pro-
teins analyzed (46%). On the other hand, all these nine proteins
Table 1. Proteins Significantly Upregulated in at Least Two of the Three Proteomics Screens in Cdh1-Deficient Cellsa
Symbol Uniprot Description
Log2 KO/WT
Async. MEFs
Log2 KO/WT
G0 MEFs
Log2 KO/WT
Brains KENb D Boxc RXXLd Reference
Top2a Q01320 DNA topoisomerase
2-alpha
1.584 1.222 2.01 1 2 5
Kif11 Q6P9P6 Kinesin-like protein
KIF11 (Eg5)
1.72 0.996 1.374 1 — 3
Ckap2 Q3V1H1 Cytoskeleton-associated
protein 2
2.116 1.024 0.845 1 — 2 Hong et al., 2007;
Seki and Fang, 2007
Kpna2 P52293 Importin subunit alpha-2 1.729 0.737 1.145 — — 2
Tacc3 Q9JJ11 Transforming acidic
coiled-coil-containing
protein 3
ND 0.845 1.959 2 — 2 Jeng et al., 2009
Anln Q8K298 Actin-binding protein
anillin
1.668 0.983 ND — 3 11 Zhao and Fang, 2005
Cbr2 P08074 Carbonyl reductase
[NADPH] 2
1.696 0.774 ND — — 1
Krt2 Q3TTY5 Keratin, type II
cytoskeletal 2 epidermal
ND 0.66 0.977 — 2 3
BubR1 Q9Z1S0 Mitotic checkpoint
serine/threonine-protein
kinase BUB1 b
ND 0.683 0.655 2 3 7
ND, not detected.
aKnown candidates are accompanied by the corresponding references.
bThe number of KEN boxes (K-E-N).
cThe number of D boxes (R-X-X-L-X-[LIVM]) as defined in the Eukaryotic Linear Motif resource (http://elm.eu.org/).
dThe number of relaxed D boxes (R-X-X-L). The presence of these three domains (KEN, D box, and RXXL) was analyzed with ScanProsite (http://
prosite.expasy.org/scanprosite/).(100%versus 83% in the set of 5,997 proteins; p < 0.001) contain
a relaxed D box as defined by the R-X-X-L sequence (Table 1).
Cdh1 Controls the Protein Levels of Eg5 and Top2a in
Mouse and Human Cells
We next tested the effect of Cdh1 overexpression or down-
regulation in human cells. Human 293T cells were transfected
with vectors expressing Cdc20, Cdh1, or a hyperactive Cdh1
mutant (Cdh1ALA) carrying nine mutations that make this protein
insensitive to its inhibition by Cdk-dependent phosphorylation
(Kramer et al., 2000). As shown in Figure 3A, expression of either
Cdh1 or Cdh1ALA resulted in downregulation of Eg5, Top2a, as
well as known Cdh1 substrates. These differences were not
due to changes in cell-cycle profile because overexpression of
these APC/C cofactors did not change DNA content in these
cultures (Figure S2). In these assays, Cdc20 induced down-
regulation of its substrate securin, but not the other molecules.
On the other hand, knockdown of Cdh1 in human cells resulted
in increased levels of Eg5 and Top2a, similarly to known sub-
strates such as Tpx2 and Aurora A (Figure 3B). The upregulation
of Eg5 and Top2a in Cdh1-null cells was not a consequence of
increased transcription because the levels of the corresponding
transcripts were not increased (Figure 3C). These mutant cells,
however, displayed a significant transcriptional upregulation of
p21Cip1 and Gadd45a, in agreement with the DNA-damage-like
response in these cells and their increased susceptibility to
become senescent (Eguren et al., 2013; Garcı´a-Higuera et al.,
2008; Li et al., 2008). Both Eg5 and Top2awere unstable proteinsCafter the inhibition of protein synthesis with cycloheximide
(Figure 3D) or actinomycin D (Figure S2). Importantly, the levels
of these two proteins, similarly to Aurora A, were partially stabi-
lized in Cdh1-null cells. Reintroduction of exogenous Cdh1 in
Fzr1(–/–) cells restored the levels of Eg5 and Top2a, and this
was dependent on the proteasome (Figure 3E). Finally, coimmu-
noprecipitation studies indicated that Cdh1 was able to bind
both Eg5 (Figure 3F) and Top2a (Figure 3G), supporting a role
for APC/C-Cdh1 in the degradation of these two proteins.
We then tested the direct ubiquitination of these two proteins
by APC/C-Cdh1 complexes using cell-free ubiquitination and
destruction assays in Xenopus egg extracts. As shown in Figures
3H and S3, Eg5 was ubiquitinated and degraded after the
addition of recombinant Cdh1 protein in these assays. Both
Cdh1-dependent ubiquitination and degradation were pre-
vented after mutagenesis of a KEN box sequence (amino acids
[aa] 1,022–1,024 in the human Eg5 sequence) and two D box
sequences (aa 944–947 and 1,047–1,050; Figure S3). Accord-
ingly, the Eg5 isoform carrying these three mutations (Eg5_3M)
was unable to efficiently bind Cdh1 (Figure S3). Top2a was not
efficiently degraded in a similar assay in Xenopus egg extracts
(Figure 3I). However, Top2awas ubiquitinated in a Cdh1-depen-
dent manner following a similar kinetics to that observed for Eg5,
and its ubiquitination was lost in a Top2a mutant carrying
specific mutations in a KEN box (aa 378–380) and two putative
D boxes (aa 982–985 and 1,053–1,056 in the human sequence;
Figure 3I and S3). These data suggest that both Eg5 and
Top2a are ubiquitinated in a Cdh1-dependent manner.ell Reports 6, 670–683, February 27, 2014 ª2014 The Authors 673
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Figure 3. Cdh1 Controls Eg5 and Top2a
Protein Stability
(A) Protein levels of the indicated molecules after
overexpression of Cdh1 (wild-type form or the
Cdh1ALA constitutive active mutant) or Cdc20 in
human 293T cells.
(B) Protein levels of the indicated molecules 72 hr
after transfection of 293T cells with a short hairpin
RNA against Cdh1 or against scrambled (Scr.)
sequences.
(C) Quantification (log10 scale) of mRNA levels of
the indicated transcripts by real-time RT-PCR.
Cdkn1a is the symbol of the locus encoding the
p53-responsive cell-cycle inhibitor p21Cip1.
(D) Protein stability of the indicated molecules in
the presence of cycloheximide (CHX) in Cdh1-null
and control cells. The quantification of protein
levels (mean ± SEM) at 0 and 6 after the addition of
CHX is shown.
(E) Protein levels of the indicated molecules after
expression of Cdh1 in Fzr1(–/–) MEFs in the pres-
ence or absence of the proteasome inhibitor
MG132.
(F and G) Coimmunoprecipitation studies in 293T
cells transfected with Eg5 (F) or Top2a (G) -GFP
fusion proteins. Protein extracts were immuno-
precipitated with antibodies against GFP (a-GFP),
and the endogenous Cdh1 was detected in the
absence or presence of the proteasome inhibitor
MG132.
(H) Cdh1-dependent ubiquitination and destruc-
tion of Eg5. 35S-labeled wild-type or triple mutant
(3M; see Figure S3) Eg5 were subjected to an
in vitro ubiquitination assay using purified Xenopus
APC/C in the presence or absence of Cdh1 (upper
panel) or a cell-free destruction assay recon-
stituted in Xenopus egg interphase extracts in the
presence or absence of Cdh1 (lower panel).
(I) Similar ubiquitination and destruction assays
with wild-type or triple mutant (3M) Top2a. These
blots are representative of three different assays.Cdh1-Dependent Degradation of Eg5 and Top2a
Contributes to Genomic Stability
We first synchronized MEFs in prometaphase by releasing
these cells from double thymidine block in the presence of
taxol. Mitotic cells were then selected by shake-off, plated in
the absence of taxol, and harvested at different time points
for protein analysis. Endogenous Eg5 was degraded during
mitotic exit with a kinetics similar to that of known APC/C-
Cdh1 substrates such as Tpx2 or Aurora kinase B, and slower
than APC/C-Cdc20 substrates such as cyclin B1 or securin (Fig-
ures 4A and 4B). Importantly, the levels of all these substrates674 Cell Reports 6, 670–683, February 27, 2014 ª2014 The Authorswere stabilized during mitotic exit in
Cdh1-null cells (Figures 4A and S3).
Mutation of the KEN box partially
stabilized Eg5 during mitotic exit in a
similar experimental setting, and this
effect was further enhanced upon
mutation of the two putative D boxes
present in this protein (Figure S3). Time-lapse studies in NIH 3T3 cells also showed that Eg5 is degraded
during telophase and maintained at low levels during the
following G1 phase, whereas the levels of the triple mutant
(Eg5_3M) remained high in the cytoplasm of interphasic
cells (Figures 4C and 4D). Similar assays indicated that
Top2a was degraded in a gradual manner after mitotic exit,
and most of its degradation occurred after several hours in G1.
Importantly, the Top2a_3M mutant displayed a significant
stabilization (Figures 4C and 4D) in agreement with a role for
the APC/C-Cdh1 recognition sites in the degradation of this
molecule.
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Figure 4. Degradation of the Kinesin Eg5 during Mitotic Exit
(A) Protein levels of the indicated molecules at different time points after a release from taxol.
(B) Comparative profiles of the levels (mean ± SEM) of the indicated proteins after release from taxol from three different assays. Values are normalized to the
amount of protein at t = 0 (in the presence of taxol).
(C) Quantification of the degradation of Eg5- or Top2a-GFP fusion proteins during mitotic exit (after anaphase onset or DNA decondensation) as monitored by
videomicroscopy. The quantification shows the comparative levels of normal Eg5 or the Eg5_3M mutant (n = 16 cells; left panel) or wild-type Top2a or the
Top2a_3Mmutant (n = 10 cells; right panel). Cells were aligned in metaphase for Eg5 or telophase upon DNA decondensation for Top2a (t = 0), and the intensity
(mean ± SD) of the signal was arbitrarily set as 1.
(D) Representative images of mitotic progression in the presence of Eg5, Eg5_3M, Top2a, or Top2a_3M (green) GFP fusion proteins. The signal of a histone
H2B-mCherry fusion protein is in red. BF, bright field. Time 0 indicates anaphase onset (top) or mitotic exit (bottom panels). Scale bars, 25 mm.
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Overexpression of either of these molecules resulted in
increased DNA damage (as scored by the number of 53BP1
foci; Figure S4). Overexpression of Eg5 also resulted in abnormal
mitotic figures characterized by lagging chromosomes and
anaphase bridges. These abnormalities were also present after
overexpression of Top2a although the increase inmitotic aberra-
tions was not statistically significant in our assays. These
abnormal figures were also frequent in Cdh1-null cells, and
knockdown of either Eg5 or Top2a partially rescued these aber-
rations (Figure S4), suggesting that the increased levels of Eg5
and Top2amay contribute to the genomic alterations (DNA dam-
age and mitotic aberrations) found in Cdh1-null cells.
Cdh1-Dependent Degradation of Eg5 Modulates the
Response to Eg5 Inhibitors
Pioneer screens to identify antimitotic drugs led to the charac-
terization of monastrol as an Eg5 inhibitor (Mayer et al., 1999),
and several Eg5 inhibitors are now in clinical trials (Dome´nech
and Malumbres, 2013; Rath and Kozielski, 2012). Treatment
with monastrol leads to a mitotic-checkpoint-dependent
mitotic arrest and lack of chromosome segregation due to
the lack of a bipolar spindle. However, Cdh1-null cells dis-
played partial resistance to monastrol as chromosome segre-
gation occurred in more than 20% of these mutant cells in
the presence of similar levels of this drug (Figures 5A, 5B,
and S5). Importantly, this resistance was likely to be due to
the increased levels of Eg5 as concomitant downregulation of
this protein using RNA interference completely prevented chro-
mosome segregation in the presence of monastrol (Figures 5C
and 5D). Parallel knockdown of Eg5 in untreated cells resulted
in normal segregation in most cells, and only 15% of these
treated cells displayed problems during mitosis. Knockdown
of Eg5 restored susceptibility to monastrol in terms of chromo-
some segregation and also prevented the rapid exit from
mitosis observed in a few (7%; n = 45) Cdh1-null cells treated
with monastrol (Figures 5B and 5D). The resistance of Cdh1-
null cells was less evident when using increasing concentra-
tions of monastrol (Figure S5), suggesting a dosage effect in
which Cdh1 inactivation leads to Eg5 overexpression, and
this overexpression results in a partial resistance of monastrol.
In addition, these effects were specific of the Eg5 inhibitor
monastrol, given that similar studies in the presence of taxol
showed no resistance to this microtubule poison in the
absence of Cdh1 (Figure S5).
Genetic Ablation of Cdh1 Leads to Increased
Susceptibility to Topoisomerase Poisons
Compounds that target topoisomerase II are classified into two
main classes with different mechanism of action: topoisomerase
poisons (e.g., etoposide), which target the Top2a-DNA complex
after the topoisomerase has created the DNA double-stranded
break (DSB), and topoisomerase catalytic inhibitors (e.g.,
ICRF-193), which target the ATPase domain and therefore
prevent the breakage made by Top2a (Nitiss, 2009). In fact,
catalytic inhibitors are used to prevent some of the toxic effects
of poisons, because they prevent the amount of DNA breakage
in some sensitive organs such as the heart. Given that clinical
data suggest that increased levels of Top2a correlate with the676 Cell Reports 6, 670–683, February 27, 2014 ª2014 The Authorsoutcome of patients treated with topoisomerase inhibitors, we
asked whether the increased levels of Top2a observed in
Cdh1-deficient cells could modulate the sensitivity to the topo-
isomerase poison etoposide. Cdh1-deficient cells displayed a
significant increase in the number of DNA breaks generated by
etoposide as monitored by the nuclear staining of the phosphor-
ylated form of histone H2AX (gH2AX; Figures 6A and S6). These
data correlated with a dramatic increase in cell death after treat-
ment of Cdh1-null cells with etoposide, as monitored by flow
cytometry (FigureS6) or high-throughputmicroscopy (Figure 6B).
For instance, about 70% of Fzr1(–/–) cells died after treatment
with 25 mM etoposide, whereas less than 10% of control cells
were killed in these conditions. No differences were observed
in the response to the catalytic inhibitor ICR-193. However,
this inhibitor was able to protect cells from the lethality observed
after treatment with etoposide alone (Figure 6B), in agreement
with the idea that DNA damage induced by topoisomerase
poisons can be partially prevented by inhibiting the catalytic
activity of these enzymes.
We then tested whether the susceptibility of Cdh1-null cells
to etoposide is a consequence of increased Top2a expression.
Overexpression of Top2a itself resulted in certain levels of DNA
damage (Figures S4 and S6) and strongly cooperated with
etoposide in inducing high levels of gH2AX (Figure S6). We
then tried to rescue the damage in Cdh1-null cells by treating
Fzr1(–/–) and control cells with etoposide or ICRF-193 in the
presence of short hairpin RNA interfering molecules against
Top2a transcripts or scrambled sequences. Two different small
hairpin RNA (shRNA) sequences, #1284 and #2837, that display
different efficiency in downregulating Top2a were used (Fig-
ure S4). Partial downregulation of Top2a with shTop2a #1284
resulted in a significant protection against the lethal effect of
etoposide, and this effect was more dramatic when using
sequence #2837, which is more effective knocking down
Top2a (Figure 6C). It is important to note that, due to the high
levels of upregulation of Top2a in Cdh1-null cells, these hairpin
molecules were not able to modulate Top2a expression down
to the levels found in wild-type cells (Figure S4), perhaps explain-
ing that these rescued cells still displayed some sensitivity to
etoposide (Figure 6C).
Chemical Inhibition of the APC/C Sensitizes Cells to
Topoisomerase Poisons
Inhibition of the APC/C is currently considered as a therapeutic
strategy in cancer by preventing Cdc20-dependent mitotic exit
(Manchado et al., 2012). A small-molecule, proTAME, results in
mitotic arrest in collaboration with microtubule poisons by inhib-
iting APC/C-Cdc20 complexes (Zeng et al., 2010). proTAME
targets both APC/C-Cdc20 and APC/C-Cdh1 (Zeng et al.,
2010), although the effect of inhibiting Cdh1 complexes has
not been analyzed so far. As shown in Figure 7A, treatment of
HeLa cells with different concentrations of proTAME resulted in
increased levels of both Eg5 and Top2a in a dose-dependent
manner. These differences were not due to mitotic arrest
because the mitotic index of cells treated with 20 mM proTAME
was 4.6% ± 1.1% compared to 2.1% ± 0.6% in untreated
cultures. The upregulation of Top2a was also significant after
immunofluorescence with specific antibodies, and these results
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Figure 5. Absence of Cdh1 Results in Increased Resistance to Monastrol in an Eg5-Dependent Manner
(A) Plots showing the fate of individual Cdh1-null or control cells (rows) in the presence or absence of monastrol. The progression through interphase or abnormal
or normal mitosis is represented as indicated. About 12%–14% of cells die in the presence of monastrol. One-fifth of Cdh1-null cells display chromosome
segregation in the presence of monastrol, whereas this is not observed in wild-type cells (n = 45 cells per assay).
(B) Representative images of the effect of monastrol. This inhibitor prevents chromosome segregation in wild-type cells (top panels). Representative examples of
Cdh1-null cells undergoing chromosome segregation are shown in the bottom panels. Time 0 indicates mitotic entry (chromosome condensation and rounding of
cells). Histone H2B is in green. Scale bars, 25 mm.
(C) Effect of knockdown of Eg5 in Cdh1-null cells in the presence or absence of monastrol. Colors indicate cell fate as in (A). (n = 45 cells per assay.)
(D) Duration of mitosis (DOM) in the previous assays. Each dot corresponds to an individual cell (n = 45 cells per condition). Red bars indicate mean ± SD.
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Figure 6. Effect of Topoisomerase Poisons
and Catalytic Inhibitors in Cdh1-Deficient
Cells
(A) DNA damage as monitored by phosphorylation
of H2AX (gH2AX) induced by etoposide or ICRF-193
in Cdh1-null or control cells. Scale bars, 10 mm.
(B) Quantification of cell death by internalization of
the dye TO-PRO using high-throughput micro-
scopy. Cdh1-null (red) or control (black) cells were
treated with etoposide (at the indicated doses) or
ICRF-193 (5 mM). The percentage of dead cells (red
frame) is indicated for each condition.
(C) Similar quantification of cell death after treat-
ment with the indicated compounds and knock-
down of Top2a using two different short hairpin
interfering RNAs.
In (B) and (C), black horizontal bars indicate the
mean. ***p < 0.001; Student’s t test.
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Figure 7. Cdh1 Inhibition Sensitizes Human Cancer Cells to Topoisomerase Poisons
(A) Protein levels of Eg5 and Top2a 24 or 48 hr after chemical inhibition of the APC/C using proTAME at the indicated dose in HeLa cells.
(B) Quantification of Top2a levels in HeLa cells treated with the indicated dose of proTAME or etoposide (mM). Horizontal bars indicate the mean. Representative
images of cells treated with 25 mM etoposide or 25 mM etoposide + 20 mM proTAME. Top2a, red; DAPI, blue. Scale bars, 10 mM.
(C) Cellular intensity of the dye TO-PRO after treatment of HeLa cells with the indicated dose of proTAME or etoposide (mM). Mean is indicated as horizontal bars.
(D–F) Percentage of dead cells (mean, as considered in the frame shown in C ± SEM) after treatment of HeLa (D), A549 (E), or MCF7 (F) cells with the indicated
dose of proTAME and etoposide (mM). At least 4,000 cells per condition were quantified in these assays (B–F), and only 1,000 are represented in (B) and (C)
for clarity.
See Figure S7 for additional cell types. n.s., not significant; **p < 0.01; ***p < 0.001; Student’s t test.
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were also obtained in different cell types such as lung cancer
cells (A549) and breast tumor cells (MCF7; Figure 7B and S7).
Importantly, inhibition of the APC/C with proTAME sensitized
HeLa cells to etoposide. Whereas single treatment with pro-
TAME or etoposide resulted in certain levels of lethality in HeLa
cells, the combination of these two compounds resulted in a sig-
nificant synergism, especially when low dose of proTAME was
used (Figures 7C and 7D). In A549 cells, treatment with 10 mM
of proTAME resulted in no dramatic differences in Top2a levels
(Figure S7), and, accordingly, no differences in lethality were
observed (Figure 7E). A combination of 20 mM of proTAME and
25 mM of etoposide resulted in a significant synergism in killing
A549 cells, whereas higher concentrations of etoposide
(100 mM) were not modulated by proTAME, suggesting that the
combination of these two compounds is efficient in a specific
window of moderate concentrations. Similarly, the synergism
of this combination was evident using 10 mM of proTAME in
MCF7 breast cancer cells, and much more dramatic when using
20 mM of this APC/C inhibitor in the presence of moderate con-
centrations of etoposide (Figure 7F). These concentrations of
proTAME induced a dramatic upregulation of Top2a (Figure S7),
suggesting that the therapeutic effect of this APC/C inhibitor cor-
relates with its ability to induce Top2a accumulation.
DISCUSSION
We have made use of a combination of genetic and proteomic
approaches to analyze major changes in protein levels in APC/
C-Cdh1-deficient cells. Among the candidates, we have focused
in this study in two molecules that scored among the highest
accumulated proteins in three different proteomic analyses in
Cdh1-null cells or tissues.
Eg5, also known as Kif11, is a bipolar, homotetrameric, plus-
end-directed spindle motor protein of the kinesin-5 family
involved in the proper formation of a bipolar spindle. Earlier
work in budding yeast suggested that the related Cin8p and
Kip1p kinesins are degraded in an APC/C-dependent manner.
Cdc20-dependent degradation of Kip1p seems to depend on
a 17 aa sequence with no primary homology to other known
domains (Gordon and Roof, 2001), whereas degradation of
Cin8p is Cdh1-dependent, although this protein also lacks a
functional D box sequence (Hildebrandt and Hoyt, 2001). In
mammals, overexpression of Eg5 results in mitotic defects in
cultured cells (Figure S4) as well as genomic instability and tumor
development in vivo (Castillo et al., 2007). In addition, this protein
is commonly overexpressed in human tumors, and, given its
function during mitotic progression, is currently under clinical
evaluation as a cancer target (Dome´nech and Malumbres,
2013; Rath and Kozielski, 2012). Treatment of cells with the
Eg5 inhibitor monastrol results in monopolar spindles and a
mitotic arrest that depends on the activity of the mitotic
checkpoint. Lack of Cdh1, however, results in partial resistance
to monastrol, but not taxol, and this resistance is at least partially
dependent on the increased Eg5 levels in thesemutant cells. The
correlation between Eg5 expression and the response to Eg5
inhibitors remains to be reported in clinical trials. Yet, Eg5 levels
may correlate with the response to different antimitotic drugs
combined with classical chemotherapies (Saijo et al., 2006).680 Cell Reports 6, 670–683, February 27, 2014 ª2014 The AuthorsThe control of Eg5 by Cdh1 may also have additional clinical
implications as the activity of this kinesin is also altered in human
microcephaly (Ostergaard et al., 2012). In addition, Eg5 regulates
axonal outgrowth (Myers and Baas, 2007; Nadar et al., 2008) and
neuronal development (Ferhat et al., 1998) and migration (Falni-
kar et al., 2011). Inhibition of Eg5 is also currently considered as
a strategy to improve axon regeneration (Haque et al., 2004; Lin
et al., 2011). Importantly, Cdh1 has also been shown to be
expressed in neural progenitors (Eguren et al., 2013) and post-
mitotic neurons (Gieffers et al., 1999), regulates axonal growth
(Konishi et al., 2004), and may be involved in neurodegenerative
diseases in the mammalian brain (Aulia and Tang, 2006).
Proteomic analysis of Cdh1-null cells shows that Top2a is one
of the most accumulated proteins in the absence of this APC/C
cofactor (Figures 1 and 2). Top2a is known to be regulated
by protein degradation although reported data suggest that
this occurs in a Bmi1/Ring1A-dependent manner in the presence
of DNA damage (Alchanati et al., 2009). Our data suggest that
Top2a is ubiquitinated and degraded in a Cdh1-dependent
manner during G1, and its ubiquitination and degradation can
be prevented after mutation of specific KEN and D boxes (Fig-
ures 3 and 4). The kinetics of degradation of Top2a differs from
other typical Cdh1 substrates in that this protein is degraded
later in G1 rather than during mitotic exit (Figure 4; Heck et al.,
1988; Tavormina et al., 2002), suggesting additional require-
ments that are unknown at this moment.
Topoisomerase poisons such as etoposide block the catalytic
cycle after DNA is already cleaved by topoisomerase but before
DNA religation, thus generating Top2-DNA covalent complexes.
These poisons therefore convert Top2 into an agent that induces
cellular damage (Nitiss, 2009). Cdh1-null cells are known to
display high levels of DNA damage both in vitro (Sigl et al.,
2009) and in vivo (Eguren et al., 2013). Lack of Cdh1 results in
increased levels of Cyclin-Cdk activity and premature entry
into S phase (Garcı´a-Higuera et al., 2008), and partial inhibition
of Cdk activity results in reduced replicative stress in Cdh1-null
cells (Eguren et al., 2013). It is likely that the increased levels of
Top2a in Cdh1-null cells contribute not only to the increased
sensitivity to etoposide (Figures 6 and 7), but also to the DNA
damage and genomic instability observed in the absence of
this APC/C cofactor. Whereas Top2a is the main topoisomerase
isoform expressed in proliferating cells, a switch in the protein
levels from Top2a to Top2b occurs during neuronal differentia-
tion (Tiwari et al., 2012; Watanabe et al., 1994). We have recently
observed that lack of Cdh1 in the nervous system results in
accumulation of gH2AX signal, defective development of the
nervous system, and hydrocephalus (Eguren et al., 2013), sug-
gesting that the control of Top2a levels by APC/C-Cdh1 may
have a critical role during brain development.
The especial sensitivity of Cdh1-deficient cells to topoisomer-
ase poisons may also have relevant implications in cancer
therapy. Cdh1 targets for degradation many proteins involved
in cell-cycle progression, and some of its substrates display
oncogenic potential (Malumbres and Barbacid, 2009). Partial
inactivation of Cdh1 results in increased susceptibility to tumor
formation in mouse models (Garcı´a-Higuera et al., 2008). The
status of Cdh1 in human tumors has not been explored in detail.
However, Cdh1 is inhibited by Cdk-dependent phosphorylation
(Kramer et al., 2000), and this cofactor is possibly inactive in
cancer cells due to Cdk hyperactivity (Lehman et al., 2007). As
shown in this work, Cdh1-deficient cells display an increased
susceptibility to topoisomerase poisons (Figure 6). Overexpres-
sion of Top2a is known to correlate with susceptibility to these
drugs (Figure S6; (Coutts et al., 1993; Keith et al., 1993; Smith
et al., 1993), and it will be therefore interesting to test in human
tumors whether Cdh1 may be useful as a biomarker for thera-
peutic strategies based on the use of topoisomerase poisons.
Direct inhibition of the APC/C has been recently proposed as
a therapeutic strategy based on the sensitivity of the mitotic-
arrested cells generated upon Cdc20 inactivation to die (Huang
et al., 2009; Manchado et al., 2010b; Manchado et al., 2012).
Here, we have shown that the inhibition of APC/C may have
therapeutic use, not only by inhibiting Cdc20 (Manchado et al.,
2010b; Zeng et al., 2010), but also by altering the levels
of Cdh1 substrates. In particular, APC/C-Cdh1 inhibition by
small-molecule inhibitors specifically increases Top2a levels
and sensitizes cells to topoisomerase poisons. These results
provide a scenario for exploring the relevance of inhibiting the
APC/C with independence of its mitotic effect. Given the rele-
vance of topoisomerase poisons in the clinic (Nitiss, 2009), these
data may open avenues to explore the relevance of synthetic
lethal interactions based on APC/C-Cdh1 substrates.
EXPERIMENTAL PROCEDURES
Mice and Cell Culture
Cdh1-deficient mice were reported previously (Garcı´a-Higuera et al., 2008).
Mice were housed in the pathogen-free animal facility of the Spanish National
Cancer Research Centre (CNIO, Madrid) following the animal care standards
of the institution. All animal protocols were approved by the ISCIII committee
(Madrid) for animal care and research. For histological observation, dissected
organs were fixed in 10%-buffered formalin (Sigma-Aldrich-Aldrich) and
embedded in paraffin wax. Sections of 3 or 5 mm thickness were stained
with hematoxylin and eosin (H&E). Additional immunohistochemical examina-
tion of the tissues and pathologies analyzed were performed using specific
antibodies (Table S2).
MEFs were isolated from mutant and control embryos and cultured using
routine procedures (Garcı´a-Higuera et al., 2008). Etoposide (Sigma-
Aldrich-Aldrich; 25-100 mM), ICRF-193 (Sigma-Aldrich-Aldrich, 5 mM), monas-
trol (Sigma-Aldrich; 100 mM), taxol (Sigma-Aldrich; 1 mM), proTAME (Boston
Biochem; 10–20 mM), cycloheximide (Sigma-Aldrich; 100 mg/ml), and actino-
mycin D (Sigma-Aldrich; 1 mM) were used at the indicated concentrations.
For quantitative RT-PCR studies, total RNA was isolated by using the
QIAGEN RNeasy kit, according to the manufacturer’s instructions. cDNA
was synthesized with a Superscript III reverse transcriptase (Invitrogen), and
PCR amplificationwas performed using SYBRGreen PCRMaster mix (Applied
Biosystems) with specific primers (Table S3).
Proteomic Analysis
For SILAC analysis, equal number of asynchronous Fzr1(+/+) (light labeled)
and Fzr1(–/–) (heavy labeled) mouse MEFs were mixed. For iTRAQ assays in
cultured cells, primary MEFs were synchronized in G0 by confluence and
low serum (0.1% FBS) for 36 hr. For iTRAQ studies in brains, E15.5 embryo
brains from Fzr1(–/D)(Garcı´a-Higuera et al., 2008) and control mice were lysed.
Three different clones of MEFs or three different brains of each genotype were
used in these assays. Protein samples were digested using the filter aided
sample preparation method (Wisniewski et al., 2009), and samples were
fractionated on the basis of their isolectric point (Ernoult et al., 2008) using
the 3100 OFFGEL Fractionator system (Agilent Technologies). Peptide sam-
ples were analyzed by LC-MS/MS using an LTQ Orbitrap Velos. Additional
specific details are provided as Supplemental Information.CImmunoblot and Immunofluorescence
Cultured cells were lysed in RIPA or Laemmli buffer. Embryonic brains
were lysed in 6 M urea, 2 M thiourea, 1% N-octyl glucoside, 10 mM DTT,
100 mM HEPES (pH 8.0) plus protease inhibitors, phosphatase inhibitors
cocktail I and 2 (Sigma-Aldrich-Aldrich), and 0.1% Benzonase nuclease
(Novagen). Fifty micrograms of total protein was separated by SDS-PAGE,
transferred to nitrocellulose membranes (Bio-Rad), and probed with different
antibodies (Table S2). The secondary antibodies were HRP-conjugated anti-
bodies (DAKO), and the immunoblots were developed using the ECL system
(PerkinElmer).
For immunofluorescence, cells were fixed in 4%buffered paraformaldehyde
for 10 min at room temperature (RT), permeabilized in 0.15% Triton X-100 for
5–10 min at RT, and stained with the indicated antibodies (Table S2) and/or
with 4,6 diaminophenylindole (DAPI; Prolong Gold antifade, Invitrogen) to
visualize nuclei. Images were captured using a laser scanning confocal
microscope TCS-SP5 (AOBS) Leica or a Leica DMI 6000B microscope.
Tissues were fixed in 10%-buffered formalin (Sigma-Aldrich) and embedded
in paraffin wax. Tissue sections were blocked with 3% BSA and incubated
with primary antibodies (Table S2) for 1–2 hr at RT or 24 hr at 4C. Secondary
antibodies (Alexa 488, 594, or 647) from Molecular Probes (Invitrogen) were
used, and images were obtained using a laser scanning confocal microscope
TCS-SP5 (AOBS) Leica.High-Throughput Microscopy and Videomicroscopy
For high-throughput microscopy (HTM), cells were grown on mCLEAR bottom
96-well plates (Greiner Bio-One). After 24 hr with etoposide and/or ICRF, 1 mM
TO-PRO-3 Iodide (642/661; Invitrogen T3605) and 5 mg/ml Hoechst 33342
(Invitrogen H3570) were added. After 30 min at 37C, images were automati-
cally acquired from each well by an Opera High-Content Screening System
(PerkinElmer). A 203 magnification lens was used, and pictures were taken
at nonsaturating conditions. For videomicroscopy, cells were plated on
eight-well glass-bottom dishes (Ibidi) and imaged with a DeltaVision RT imag-
ing system (Applied Precision, LLC; IX70/71; Olympus) equippedwith a Pl APO
203/1.42 NA objective lens, maintained at 37C in a humidified CO2 chamber.
Images were acquired every 10 min. Images were processed and analyzed
using ImageJ software.Degradation and Ubiquitination Assays
Xenopus cytostatic factor-arrested egg extracts (CSF extracts) were prepared
as described previously (Murray et al., 1989). Cell-free APC/C-Cdh1-depen-
dent assays were reconstituted by adding 280 nM purified Xenopus His-
Cdh1 protein to interphase egg extracts (Trickey et al., 2013). To produce
35S-labeled substrates, mRNAs were first synthesized using mMESSAGE
mMACHINE kit (Ambion) and then translated using Rabbit Reticulocyte Lysate
System (Promega).Statistical Analysis
Statistical analysis was carried out using Prism 5 (GraphPad). All statistical
tests were performed using two-sided, unpaired Student’s t tests, or the
Fisher’s exact test. Data with p < 0.05 were considered statistically significant
(*p < 0.05; **p < 0.01; ***p < 0.001).ACCESSION NUMBERS
The mass spectrometry proteomics data have been deposited to the Proteo-
meXchange Consortium (http://proteomecentral.proteomexchange.org) via
the PRIDE partner repository (Vizcaı´no et al., 2013) under accession number
PXD000511.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and three tables and can be found with this article online at
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